Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.82 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860266 | 0.93 | HSD11B1 (0.77) | HSD11B1ROCK2NPC1RAB9AATM | |
| SCHEMBL3932779 | 0.93 | HSD11B1 (0.77) | HSD11B1ROCK2NPC1RAB9AATM | |
| SCHEMBL1860418 | 0.91 | HSD11B1 (0.85) | HSD11B1ROCK2NPC1RAB9AATM | |
| SCHEMBL1858468 | 0.90 | HSD11B1 (1.00) | HSD11B1ROCK2 | |
| SCHEMBL1856868 | 0.89 | HSD11B1 (0.81) | HSD11B1ROCK2 | |
| SCHEMBL1860793 | 0.87 | HSD11B1 (0.79) | HSD11B1ROCK2 | |
| SCHEMBL1856402 | 0.87 | HSD11B1 (1.00) | HSD11B1ROCK2NPC1RAB9AHPGD | |
| SCHEMBL1860157 | 0.86 | HSD11B1 (1.00) | HSD11B1ROCK2 | |
| SCHEMBL1856442 | 0.86 | HSD11B1 (1.00) | HSD11B1ROCK2 | |
| SCHEMBL1856437 | 0.86 | HSD11B1 (1.00) | HSD11B1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2044057-A2 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008000950-A2 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | HSD11B1 1/4885ROCK2 3507/4885NPC1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.